Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing
Li‐Qiang Sun(Bristol-Myers Squibb (United States)), William Warner(Bristol-Myers Squibb (United States)), Barbara Zheng(Bristol-Myers Squibb (United States)), Anthony J. Cocuzza(Bristol-Myers Squibb (United States)), Jay O. Knipe(Bristol-Myers Squibb (United States)), Paul Falk(Bristol-Myers Squibb (United States)), Hong Shi(Bristol-Myers Squibb (United States)), Maria Donoso(Bristol-Myers Squibb (United States)), Stephen Adams(Bristol-Myers Squibb (Germany)), Arvind Mathur(Bristol-Myers Squibb (United States)), Bang‐Chi Chen(Bristol-Myers Squibb (United States)), Steven M. LeVine(Kaiser Permanente Oakland Medical Center), Jacques Friborg(Bristol-Myers Squibb (United States)), Paul Lévesque(Bristol-Myers Squibb (United States)), Donna M. Bilder(Bristol-Myers Squibb (United States)), Alicia Ng(Bristol-Myers Squibb (United States)), Eric Mull(Bristol-Myers Squibb (United States)), Tatyana Zvyaga(Bristol-Myers Squibb (Germany)), Richard Schartman(Bristol-Myers Squibb (Germany)), Herbert E. Klei(Bristol-Myers Squibb (United States)), Qi Gao(Merck & Co., Inc., Rahway, NJ, USA (United States)), Stanley V. D’Andrea(Bristol-Myers Squibb (United States)), Alan Xiangdong Wang(Bristol-Myers Squibb (United States)), Ramkumar Rajamani(Bristol-Myers Squibb (United States)), Brian L. Venables(Bristol-Myers Squibb (United States)), Pirama Nayagam Arunachalam(Bristol-Myers Squibb (India)), Jeffrey Tredup(Bristol-Myers Squibb (United States)), Theerthagiri Palani(Bristol-Myers Squibb (India)), Michael Sinz(Rutgers, The State University of New Jersey), Fei Yu(Yunnan Academy of Agricultural Sciences), Richard Rampulla(Bristol-Myers Squibb (United States)), Kevin Kish(Bristol-Myers Squibb (United States)), Jie Chen(Renji Hospital), Dennis Hernandez(Bristol-Myers Squibb (United States)), Amy K. Sheaffer(Bristol-Myers Squibb (United States)), Ny Sin(Bristol-Myers Squibb (United States)), Sivakumar Ganesan(Bristol-Myers Squibb (India)), Chaoqun Chen(Bristol-Myers Squibb (United States)), Yong–Hae Han(Bristol-Myers Squibb (United States)), Dennis M. Grasela(Bristol-Myers Squibb (United States)), James Loy(Bristol-Myers Squibb (United States)), Sing‐Yuen Sit(Bristol-Myers Squibb (United States)), Kathy Mosure(Bristol-Myers Squibb (United States)), Qian Zhao(Bristol-Myers Squibb (United States)), Luciano Mueller(Bristol-Myers Squibb (United States))
Cited by 31
Related Papers
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
|Nature|2010|940
CYP3A4 Induction by Drugs: Correlation between a Pregnane X Receptor Reporter Gene Assay and CYP3A4 Expression in Human Hepatocytes
|Drug Metabolism and Disposition|2002|447
Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy
|Signal Transduction and Targeted Therapy|2021|352
Entecavir resistance is rare in nucleoside naïve patients with hepatitis B
|Hepatology|2006|348
Inactivation of Cytochrome P450 3A4 by Bergamottin, a Component of Grapefruit Juice
|Chemical Research in Toxicology|1998|312